key: cord-0281422-1yha2qee
authors: Eugenia-Toledo-Romani, M.; Garcia-Carmenate, M.; Verdecia-Sanchez, L.; Perez-Rodriguez, S.; Rodriguez-Gonzalez, M.; Valenzuela-Silva, C.; Paredes-Moreno, B.; Sanchez-Ramirez, B.; Gonzalez-Mugica, R.; Hernandez-Garcia, T.; Orosa-Vazquez, I.; Diaz-Hernandez, M.; Perez-Guevara, M. T.; Enriquez-Puertas, J.; Noa-Romero, E.; Palenzuela-Diaz, A.; Baro-Roman, G.; Mendoza-Hernandez, I.; Munoz, Y.; Gomez-Maceo, Y.; Santos Vega, B. L.; Fernandez-Castillo, S.; Climent-Ruiz, Y.; Rodriguez-Noda, L. M.; Santana-Mederos, D.; Garcia-Vega, Y.; Wu-Chen, G.; Doroud, D.; Biglari, A.; Boggiano-Ayo, T.; Valdes-Balbi,
title: Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
date: 2022-01-05
journal: nan
DOI: 10.1101/2022.01.01.21268271
sha: eda7b3e008619fa6047e79f856e5f7ba8cc304df
doc_id: 281422
cord_uid: 1yha2qee

Background: We report results of immunogenicity, safety and reactogenicity of SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial. Method: This phase IIb trial was designed as parallel, multicentre, adaptive, double blind, randomized and placebo-controlled. Subjects (N=810) aged 19-80 years were randomized to receive two doses of the recombinant SARS CoV-2 receptor binding domain (RBD) conjugated to tetanus toxoid (SOBERANA 02) and a third dose of dimeric RBD (SOBERANA Plus) 28 days apart; two production batches of active ingredient of SOBERANA 02 were evaluated. Primary outcome was the percentage of seroconverted subjects with [≥]4-fold the anti-RBD IgG concentration. Secondary outcomes were safety, reactogenicity and neutralizing antibodies. Results: Seroconversion rate in vaccinees was respectively 76.3 and 96.8% after two or three doses, compared with 7.3% in placebo group. Anti-RBD IgG increased significantly after first and second dose of SOBERANA 02 respect to placebo group; and the third dose with SOBERANA Plus boosts the response compared to the second dose. Neutralizing IgG antibodies were detected against D614G and VOCs , {beta} and {delta}. Specific and functional antibodies were detected until 7-8 months after the third dose. The frequency of serious adverse events (AEs) associated with vaccination was very low (0.1%); with only one serious AE consistent with vaccination. Local pain was the most frequent AE. Conclusions: Two doses of SOBERANA 02 were well tolerated, safe an immunogenic in adults aged 19-80 years old. The heterologous combination with a third dose of SOBERANA Plus increased neutralizing antibodies, detectable 7-8 months after the third dose. Trial registry: https://rpcec.sld.cu/trials/RPCEC00000347

COVID-19 disease has led to an unprecedented effort in vaccine development and several vaccines based on different platforms have received emergency use authorization [1] . Despite the outstanding progress, equal access to vaccines continues being a major challenge [2] .

SOBERANA 02 is an anti-SARS-CoV-2 vaccine candidate having as immunogen the recombinant RBD protein conjugated to tetanus toxoid [3, 4] . Phase I study evaluated safety, reactogenicity and immunogenicity of SOBERANA 02 at two doses (15 and 25 µg) in adults 19-59 years-old and compared SOBERANA 02 in a three-dose (homologous) schedule vs. an heterologous schedule (two doses of SOBERANA 02 and a third dose of SOBERANA Plus, a vaccine candidate whose active pharmaceutical ingredient is the RBD dimer) [5] . After an interim analysis, the higher dose (SOBERANA 02, 25 µg) was selected for phase II study [6] designed in two stages (IIa and IIb); IIa was an open trial evaluating the homologous and heterologous schedules in adults 19-80 years-old [7] . A pooled analysis of both phases I and IIa concluded that the heterologous scheme was safe, well tolerated and elicited the highest immune response, reinforcing memory cells [6] .

Here, we report immunogenicity, safety and reactogenicity of two doses of SOBERANA 02 and the heterologous scheme with a third dose with SOBERANA Plus in a randomized, double blind, placebo controlled phase IIb clinical trial.

Phase IIb was designed as a multicenter, adaptive, parallel, double blind, randomized, placebo controlled trial for evaluating the immunogenicity, safety and reactogenicity of 6 two doses of SOBERANA 02 and the heterologous scheme with a third dose with SOBERANA Plus. Healthy adults aged perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 5, 2022. ; 7 SOBERANA Plus batches were EC-CVRBDd-2008 and EC-CVRBDd-2101; placebo batch was: E1001PS02. Vaccines composition has been described previously [6] ; the placebo contained the excipients of SOBERANA 02. Vaccine and placebo formulations were visually undistinguishable.

The phase II clinical trial protocol was reviewed and approved by an ad hoc centralized The trial was conducted following the Declaration of Helsinki, Good Clinical Practice and the rules of the Cuban National Immunization Program. During participants recruitment, the investigators provided the potential participants all relevant information (both orally and written) about the vaccine candidates, and the potential risks and benefits of the trial.

All questions and doubts were clarified before enrollment. The decision to participate in the study was voluntary and not remunerated. Written informed consent was obtained from all participants. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Participants received intramuscular injections in the deltoid region, 28 days apart. They were closely followed for one hour after each injection for safety evaluation. Medical visits were planned at 24, 48 and 72 hours, 14 and 28 days after each dose. Any adverse event was self-registered by the participants on a diary card and recorder during medical visits.

Serum samples were collected on days 0 (baseline) and 56 from all subjects; on days 14 and 70, blood samples were taken from 50% of the participants while samples from the other 50% were collected on days 42 and 84. To evaluate the duration of the humoral response, seven to eight months after completing the vaccination schedule, and after signing a new informed consent, another serum sample was obtained from a subset of vaccinated participants.

The primary outcomes were percentage of subjects with seroconversion ≥4-fold the anti-RBD IgG pre-vaccination level. Secondary outcomes included: 1) Serious Adverse Events (AEs) measured daily for 28 days after each dose; 2) Solicited Local and Systemic AEs for 7 days after each dose; 3) Unsolicited AEs measured daily for 28 days after each dose; 4) Conventional neutralizing antibody titers (cVNT50) of a subset of samples from seroconverted subjects and 5) Inhibition of RBD-hACE2 interaction expressed as % and molecular inhibitory titer (mVNT50). Outcomes are detailed in Supplementary Material, Appendix A-2).

All immunological evaluations were performed by external laboratories on blind samples.

Anti-RBD IgG response and molecular-and conventional-virus neutralization titers were evaluated as described [6] (See Supplementary Materials Appendix C). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 5, 2022. ; 9 Anti-RBD IgG concentration, inhibition of RBD-hACE2 interaction and mVNT50 were determined on days 0, 14, 42, 56, 70, 84. Conventional neutralizing antibody titers (cVNT50) against D614G variant was evaluated in a subset of samples randomly selected from the individuals with seroconversion on days 0, 56, 70 and 84. cVNT50 against VOC was also determined in a subset of samples with cVNT50 vs. D614G >20. Molecular neutralization assay (% Inhibition RBD:hACE2) was determined at T0 only if the sample has pre-vaccination IgG concentration over 7.8 AU/ml (4-fold the limit of quantification in ELISA assay, 1.95 AU/ml). Anti-RBD IgG concentration, and mVNT50 were also determined after 7-8 months of the last dose. 

Solicited local and systemic AEs were measured daily from days 0 to 7 following each immunization. Other AEs were self-recorded until completion of the 28 days follow-up period. The severity of solicited AEs was graded according to Brighton Collaboration definition and the Common Terminology Criteria for Adverse Events version 5·0. All AEs were reviewed for causality, and classified according to WHO [9] .

Calculation of sample size was done before starting phase II study (this included phases IIa and IIb) considering a two-sided 95% confidence interval for the difference between two proportions with a width equal to 0.16, to estimate a difference between each API batch and placebo group of around 50%, with a lower bound of the confidence interval greater than 30% and a dropout of 15%. This resulted in a phase II sample size of 910 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.01.21268271 doi: medRxiv preprint 10 subjects randomized 4:4:1 in three groups (vaccine API 1, vaccine API 2 and placebo) (404:404:102), and allowing a loss of up to 138 subjects. Stage IIb excluded the 100 participants in phase IIa, giving a sample size of 810 subjects. The evaluation of the study hypothesis remaining valid after excluding stage IIa participants.

Safety and reactogenicity endpoints are described as frequencies (%). Quantitative demographic characteristics are reported as mean, standard deviation (SD), median, interquartile range, and range. We calculated seroconversion rate for anti-RBD IgG antibodies (≥4-fold increase in antibody concentration over baseline) for each subject.

Anti-RBD IgG concentration and % of inhibition of RBD-hACE2 interaction were expressed as median and interquartile range; molecular virus neutralization titer (mVNT50) and conventional virus neutralization titer (cVNT50) were expressed as geometric mean (GMT) and 95% confidence intervals (CI). Spearman´s rank correlation was used to assess relationships among techniques used to evaluate the immune response. The Student t-Test or the Wilcoxon Signed-Rank Test were used for beforeafter statistical comparison. Statistical analyses were done using SPSS version 25.0;

EPIDAT version 12.0 and Prism GraphPad version 6·0. An alpha signification level of 0.05 was used.

From mid-January to end-February 2021, 948 individuals were recruited for phase IIb trial, 138 were excluded and 810 included ( Figure 1 ). Eligible participants were randomly assigned for receiving vaccine (two doses of SOBERANA 02 and one dose of SOBERANA Plus) or placebo, at 28 days intervals. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.01.21268271 doi: medRxiv preprint

The demographics characteristics are summarized in Table 1 . The mean age of participants was 47 years (SD 15.8) predominating white race (73.2%).

On day 14, the proportion of subjects with ≥ 4-fold increase in anti-RBD IgG concentration was significantly different (p<0.005) in vaccine (20%) and placebo (3.8%) groups. These Table 1 ).

The conventional virus neutralization titre (cVNT50) was evaluated in a subset of samples randomly selected from participants with seroconversion after second (on T56) and third doses (on days T70 or T84). After two doses, the cVNT50 GMT was 65.9 (95% CI 46.9; 92.7), comparable to the CCSP value (GMT 41.8; 95% CI 27.7; 63.2). After the third heterologous dose a remarkable, statistically significant increase (p<0.0005) was All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 5, 2022. ; 12 observed, attaining a GMT of 219.6 (95% CI 179.5; 268.8); this is 3.3-fold the value after the second dose and 4.7-fold the value of CCSP ( Figure 2D , Supplementary materials Appendix B Table 1 ).

Neutralization against SARS-CoV-2 variants was also analyzed in sera from 18 subjects that completed the vaccination schedule. As seen in Figure 3, obtained against alpha, delta and beta variants, respectively. Compared to D614G, no differences were detected in neutralizing titres against alpha variant: however, there was a reduction of 2.32-fold and 7-fold against delta and beta variants, respectively. All analysed sera conserved neutralizing activity against alpha and delta variants, and a 94% of sera conserved activity against beta variant. Table 4 ). The proportion of subjects with seroconversion after 7-8 months (73.0%) is similar to that obtained after two doses (74.6%) (Supplementary materials Appendix B, Table 4 ). Interesting, the mVNT50 GMT (149.6; 95% CI: 122.3; 182.9)) was significantly higher than those after second dose and CCSP ( Figure 4B , Supplementary materials Appendix B, Table 4 ).

Of the 810 participants, 44.4% presented some AE. In total, 947 AEs of 80 types were reported, 92.6% classified as mild (77.3% consistent with vaccination and 70.7% related to the product under investigation). Eight serious AEs were reported (one -multiform erythema-was consistent with vaccination due to inherent conditions of the subject) (Table 2 and Supplementary materials Appendix B Table 5 ). The most frequent local solicited AE in both vaccine and placebo groups was pain at injection site (35.5% vs.

8.8%, respectively) followed by swelling (only in vaccine group, 13.0%). General discomfort (4.1% vs. 2.9%, respectively in vaccine and placebo groups) was the most frequent solicited AE at systemic level; other AEs had frequencies < 1% (Table 3) . Figure   1 , Table 6 ). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.01.21268271 doi: medRxiv preprint 14 The likelihood ratio (from Bayes factor) was used as benefit-risk index. We observed a strong evidence for benefit in the vaccine group, (Supplementary materials Appendix B, Figure 2 ).

The frequency of subjects with AEs as well as their characterization was similar in both The ability of antibodies to inhibit the interaction between recombinant RBD and the human-ACE2 receptor is a proxy for in vivo antibody affinity [20] . The virus neutralization titer was comparable to that attained by CCSP, indicating that the antibodies elicited by the immunogens-although representing only a small portion of the viral protein structure-efficiently inhibit its binding to the ACE2 receptor expressed in Vero cells. All these results are consistent with those obtained in pooled analysis of phase I and IIa clinical trials [6] .

As seen with other viruses, SARS-CoV-2 have evolved and new variants have been identified, some of them associated with higher transmissibility, mortality and decreased vaccine efficacy [21] . Epidemiology in Havana showed an evolution in variant predominance in 2021, initially D614G, then beta (March-June 2021) and finally delta (July-October 2021) [22] . We found a reduction of cVNT50 by 2.32-fold for delta, and 7fold for beta compared to D614G variant. Similar results have been observed by others: there is a 3-5-fold decrease in neutralizing antibodies against delta compared to alpha in vaccinated subjects [23] and, for the beta variant compared to the original strain, a 7.6-9-fold [24] or 10.3-12.4-fold [25] reduction in neutralization titer was observed in individuals immunized with mRNA vaccines or adenoviral-vectors.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.01.21268271 doi: medRxiv preprint 16 Immune response can be influenced by several factors like age, comorbidities and sex, as noted in other anti-SARS-CoV-2 vaccines [26, 27, 28] . Here, vaccination induced a significant increase in all immunological variables in each subgroup compared to placebo. A significantly higher response, except for cVNT50, was observed in female subjects, age group 19-59 and without comorbidities of high risk. In phase IIb the immunological response in elders´ subgroup was lower than that in 19-59 years subgroup, while in phase IIa, there were no differences between both age subgroups, except for mVNT50 [6] . This may be related to the smaller number of elderly subjects included in phase IIa (24) A prediction of clinical efficacy has been reported for seven vaccines based on immunogenicity data [30,31]. We used our cumulative data for IgG antibodies and cVNT50 from phase I, IIa and IIb (for SOBERANA 02, 25µg; two-dose and heterologous three-dose schedules) to estimate the efficacy, using the same ratio vaccinees vs. CCSP.

The efficacy for the two-dose schedule was estimated between 58% and 87% and for the three-dose scheme, between 81% and 93% (Supplementary materials Appendix B, Figure 3 ). These results have been confirmed during a phase III clinical trial conducted All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

We thank Dr. Lila Castellanos for scientific advice. We especially thank all the volunteers who participated in the clinical trial. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 5, 2022. ; 

COVID-19 vaccine tracker

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Safety and immunogenicity of a recombinant tandemrepeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

Evidence for antibody as a protective correlate for COVID-19 vaccines

Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum

An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies

Tropical Medicine Institute on the circulating strains of SARS COVID19 in Havana

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2

Impact of age, gender, ethnicity and prior disease status on immunogenicity following administration of a single dose of the BNT162b2 mRNA Covid-19 Vaccine: Real-world evidence from Israeli healthcare workers

Age-and genderdependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine